http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
간장 ( 肝臟 ) 및 담도 ( 膽道 ) : 간세포암에 대한 화학색전요법의 항종양 효과
현인영(In Young Hyun),이정애(Jung Ae Lee),고문수(Moon Soo Kih),은진호(Jin Ho Eun),염광섭(Kwang Seoup Yeoum),홍원선(Weon Seon Hong),이진오(Jhin Oh Lee),강태웅(Tae Woong Kang),변홍식(Hong Sik Byun),강숙욱(Sook Wook Kang),김기환(Kie Hwa 대한소화기학회 1991 대한소화기학회지 Vol.23 No.1
N/A Eighty-seven TACEs were performed in 38 patients with hepatocellular carcinoma: one in 16 patients; twice in seven patients; three times in seven patients; four times in four patients; and five times in four patients. In all patients, TACE was performed with adriamycin, mitomycin-C and lipiodol. In 21 patients, embolization with gelfoam powders were added following TACE. Six patients had the hepatocellular carcinoma of 4.0~4.9 cm in diameter: 14 patients, 5.0~9.9 cm; and 18 patients, larger than 10 cm. Response rate was evaluated in 33 patients, among whom fifteen patients (45$) achieved response (complete response, 6%; partial response, 33%). The cumulative survival rates at one year and two years for 38 patients were 55.3$ and 23.2%, respectively, with the median survival time of 12.0 months. Sex, ascites, HBsAg, esophageal varix, liver cirrhosis, gelfoam embolization, serum albumin level, size of the tumor, and a-fetoprotein were analyzed to investigate the effect of TACE on survival time, demonstrating that no significant differences in the survival times were observed between these factors except HBsAg. Theses results suggest that TACE is not curable for hepatocellular carcinoma, however prolong the life span in patients with hepatocellular carcinoma.